Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 20, Issue 5, 1997, Pages 369-374

  Dann, E J ^a,b   Daugherty, C K ^a   Larson, R A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Allogeneic marrow transplantation; Hodgkin's; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; HLA ANTIGEN;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; CAUSE OF DEATH; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HLA MATCHING; HODGKIN DISEASE; HUMAN; MALE; MORBIDITY; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RELAPSE; SURVIVAL; TREATMENT FAILURE;

EID: 0030750812     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700904     Document Type: Article

References (27)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1023-1030.
2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
3. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
4. Freedman AS, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524-2529.
5. Rohatiner AZ, Johnson PW, Price CG et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-1184.
6. Lazarus HM. Bone marrow transplantation in low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995; 17: 199-210.
7. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
8. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous vs allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
9. van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. Am J Med 1996; 100: 299-307.
10. Collett D. Modelling Survival Data in Medical Research. Chapman and Hall: London. 1994, p 19.
11. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-219.
12. Foucar K, McKenna RW, Frizzera G, Brunning RD. Incidence and patterns of bone marrow involvement by lymphoma in relation to the Lukes-Collins classification. Blood 1979; 54: 1417-1422.
13. Chabner BA, Johnson RE, Young RC et al. Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Ann Intern Med 1976; 85: 149-154.
14. Smith BR, Weinberg DS, Robert NJ et al. Circulating monoclonal B lymphocytes in non-Hodgkin's lymphoma. New Engl J Med 1984; 311: 1476-1481.
15. Nakano M, Kawanishi Y, Kuge S et al. Clinical and prognostic significance of monoclonal small cells in the peripheral blood and bone marrow of various B cell lymphomas. Blood 1992; 79: 3252-3260.
16. Brenner MK, Rill DR. Gene marking to improve the outcome of aulologous bone marrow transplantation. J Hematother 1994; 3: 33-36.
17. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
18. Faguet GB. Hodgkin's disease: basing treatment decisions on prognostic factors. Leuk Lymphoma 1995; 17: 223-228.
19. Vose JM, Bierman PJ, Anderson JR et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142-2148.
20. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-2534.
21. Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542,
22. Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome following autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780-3786.
23. Kwak LW, Pennington R, Longo DL. Active immunization of murine allogeneic bone marrow transplant donors with B cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996; 87: 3053-3060.
24. Renner C, Bauer S, Sahin U et al. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cell subsets in preclinical model. Blood 1996; 87: 2930-2937.
25. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J din Oncol 1993; 11: 2342-2350.
26. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
27. Chopra R, Goldstone AH, Pearce R et al. Autologous v.s allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690-1695.